Wegovy and Zepbound are the two leading FDA-approved brand-name injections for chronic weight management. Both are once-weekly injections, both come with strong clinical trial data, and both are widely offered through telehealth and in-person providers. But they differ in active ingredient, average results, and how they're typically priced. Here's the full breakdown.
Wegovy's active ingredient is semaglutide, a single-pathway GLP-1 receptor agonist. Zepbound's active ingredient is tirzepatide, a dual GLP-1/GIP receptor agonist. Both are manufactured pre-filled injection pens intended for once-weekly, at-home use.
Both medications were developed by major pharmaceutical manufacturers and went through large, multi-year clinical trial programs before receiving FDA approval specifically for chronic weight management — a distinct approval pathway from their diabetes-focused counterparts, Ozempic and Mounjaro, even though the active ingredients are identical.
| Category | Wegovy (semaglutide) | Zepbound (tirzepatide) |
|---|---|---|
| List price (before insurance/savings) | ~$1,000-$1,350 / month | ~$1,000-$1,100 / month |
| Starting dose | 0.25 mg weekly | 2.5 mg weekly |
| Typical maintenance dose | 1.7 mg - 2.4 mg weekly | 10 mg - 15 mg weekly |
| Avg. weight loss in trials | ~15% of body weight (68 wks) | ~20-22% of body weight (72 wks) |
| FDA-approved use | Chronic weight management, adults & adolescents 12+ with obesity | Chronic weight management in eligible adults |
| Injection device | Pre-filled single-dose pen | Pre-filled single-dose pen |
List prices are approximate and change frequently; manufacturer savings programs and insurance coverage can significantly lower out-of-pocket costs. Always confirm current pricing directly with your pharmacy or provider.
Both medications follow a gradual dose-escalation schedule designed to minimize gastrointestinal side effects. Wegovy starts at 0.25 mg weekly and is typically increased roughly every four weeks toward a maintenance dose of 1.7 mg or 2.4 mg. Zepbound starts at 2.5 mg weekly (a non-therapeutic starter dose) and increases toward a maintenance range of 5 mg to 15 mg, depending on tolerability and response. Providers such as MetaBloom Health and ThriveWell Rx will adjust the pace of titration based on how you're tolerating each increase.
The pen devices for both medications are designed for straightforward, at-home self-injection, typically into the abdomen, thigh, or upper arm, and both require refrigerated storage before first use. Missing a weekly dose by a day or two is generally manageable, but your provider should give you specific guidance on how to handle a missed or delayed dose rather than guessing on your own.
In Wegovy's pivotal STEP 1 trial, participants lost an average of about 15% of body weight over 68 weeks. In Zepbound's SURMOUNT-1 trial, participants on the highest studied dose lost an average of roughly 20-22% of body weight over 72 weeks. Both trials combined medication with lifestyle intervention, which is the standard of care and part of why average results were as strong as reported.
Beyond the topline weight-loss percentages, both trials also tracked secondary measures like waist circumference, blood pressure, and markers related to cardiometabolic health, with participants in both groups generally showing improvement across these measures alongside their weight loss. That broader pattern of improvement is part of why both medications are viewed as tools for overall metabolic health rather than purely cosmetic weight loss.
"On average, trial data favors Zepbound for total percentage of weight lost — but 'average' doesn't predict any one person's outcome, and tolerability matters just as much as potency." — WeightBloomX Editorial Team
Insurance coverage for both medications varies widely by plan and by whether your diagnosis meets the payer's criteria for weight management coverage. Many people pay out of pocket or use manufacturer savings cards, which can substantially reduce monthly cost for eligible patients. Some telehealth providers, including LeanCloud Care and Radiant Health Rx, also offer compounded semaglutide or tirzepatide alternatives at a lower price point — though, as with any compounded medication, these are not individually FDA-approved.
Coverage decisions can also shift from year to year as employers and insurers update their formularies, so it's worth re-checking your benefits annually even if you were denied coverage previously. Some plans that exclude weight-management coverage outright will still cover the same medication when it's prescribed for an approved diabetes diagnosis, which is one reason cost conversations are best had directly with your provider's billing team rather than assumed from a plan summary alone.
If maximizing average percentage weight loss is your top priority and you can access it at a reasonable cost, Zepbound's trial data is compelling. If you respond better to a single-pathway mechanism, have a strong preference based on a provider's recommendation, or find Wegovy more accessible through your insurance or provider network, it remains a highly effective, well-studied option. In practice, many providers will help you weigh both based on your health history and goals rather than defaulting to one.
It can also help to think about the decision as reversible rather than permanent. If you start on one medication and find the side effects difficult to manage, or the results slower than expected after a reasonable trial period, a good provider can discuss switching to the other option rather than leaving you to simply discontinue treatment altogether.
Wegovy and Zepbound are both FDA-approved, clinically proven options for chronic weight management. Zepbound has shown larger average weight loss in trials due to its dual-hormone mechanism, while Wegovy remains a well-established option with a longer real-world track record. Pricing, insurance coverage, and personal tolerability should all factor into your decision alongside the clinical data.
This article is for informational purposes only and is not medical advice. Talk to a licensed healthcare provider before starting Wegovy, Zepbound, or any GLP-1 medication.